N

North Texas Infectious Diseases Consultants | Downtown Dallas Office

Research site

(Unclaimed)

Location

3409 Worth Street Suite 710, Dallas, Texas, United States of America

Site insights

Top conditions

Top treatments

Emtricitabine

TAF

Tenofovir Alafenamide

TDF

FTC

Bictegravir

RPV

Lenacapavir

Tenofovir Disoproxil Fumarate

Islatravir

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 18 total trials

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral...

Enrolling

Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Drug: ISL/ULO

Drug: ULO

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 (ISLEND-1)

The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regi...

Active, not recruiting

HIV-1-infection

Drug: B/F/TAF

Drug: PTM ISL/LEN

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Active, not recruiting

HIV-1-infection

Drug: Stable Baseline Regimen

Drug: Bictegravir